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Mycobacterium mageritense is a recently identified 
rapidly growing uncommon mycobacteria (RGM) (1). 
Only 9 cases of skin and soft-tissue infection with M. 
mageritense have been reported to date (1–7) (Table 
I). Although accurate identification of the pathogenic 
bacteria is mandatory for efficient treatment, using 
conventional methods for the identification of M. mage-
ritense is complex and time-consuming. We report here 
a case of subcutaneous infection with M. mageritense 
that was treated successfully with antibiotics, in which 
matrix-assisted laser desorption/ionization-time of flight 
mass spectrometry (MALDI-TOF MS) (8) enabled rapid 
identification of the species.
CASE REPORT
A 70-year-old Japanese man developed subcutaneous abscesses 
in the periumbilical region within 2 weeks after a laparoscopic 
cholecystectomy. After unsuccessful treatments with antibiotics 
(cefamezin and vancomycin) and immunosuppressive agents 
(prednisolone and azathioprine) for 1 year, he was referred to our 
hospital. On examination, a total of 80 reddish nodules intermit-
tently excreting pus were observed on the abdomen (Fig. 1a). 
Histopathologically, the dermis and subcutaneous adipose tissue 
were prominently infiltrated with neutrophils (Fig. 1b, c). An 
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F/37 Yes DOXY, CFPM 9 months Cured 1
M/25 Yes AMK, IPM/CS N/A Improved 1
F/43 Yes TMP­SMX, LVFX 3 months Cured 2
F/56 No GFLX 2 months Cured 2
M/48 Yes N/A 12 months Cured 3
F/59 Yes CPFX, CAM 12 months Cured 4
M/66 Yes MLFX, CAM 4 days Cured 5
M/52 Yes CAM, LVFX 6 months Cured 6
F/85 Yes LVFX, IPM/CS, MINO 4 months Cured 7
M/70 No CAM, LVFX, MINO 7 months Cured This case
DOXY: doxycycline; CFPM: cefepime; AMK: amikacin; IPM/CS: imipenem/cilastatin; 
TMP-SMX: trimethoprim/sulfamethoxazole; LVFX: levofloxacin; GFLX: gatifloxacin; 
CPFX: ciprofloxacin; MLFX: moxifloxacin; CAM: clarithromycin; IPM/CS: imipenem/
cilastatin; MINO: minocycline; N/A: not available; F: female; M: male.
Fig. 1. Clinical pictures and histopathology. 
(a) A clinical picture before the treatment, showing 
reddish nodules on the abdomen. Arrow: scar from 
the laparoscopic cholecystectomy contiguous to the 
umbilicus. Histopathology: (b) low-magnification 
view showing a prominent infiltration of neutrophils 
in the deep dermis and subcutaneous adipose tissue. 
(c) High-magnification view of the rectangle in (b). 



























































acid-fast bacillus culture grown from the excreted pus at 37°C for 
3 days revealed a Mycobacterium species. It was identified as M. 
mageritense using MALDI TOF-MS system (Microflex LT and 
MALDI Biotyper, Bruker Daltonics GmbH) with a score value 
of 2.26 according to the MycoEx extraction protocol (v.3.0) and 
Mycobacteria Library 4.0. In addition, full-length sequencing of 
the 16S rRNA gene confirmed this finding. Based on these results, 
the patient was given a diagnosis of subcutaneous infection with 
M. mageritense.
In advance of the species identification and drug-susceptibility 
tests, we empirically administered clarithromycin (800 mg/day), 
levofloxacin (500 mg/day) and minocycline (200 mg/day). After 
initiation of these antibiotics, no new lesions emerged and the 
pre-existing eruptions began to subside. Following the species 
identification, clarithromycin was stopped because M. mageritense 
is known for its resistance to macrolides (1). Consistently, drug-
susceptibility tests later revealed that the isolate was sensitive 
to levofloxacin and minocycline and resistant to clarithromycin. 
Within 9 months after the initiation of the antibiotics, all of the sub-
cutaneous indurations had diminished, leaving post-inflammatory 
pigmentation (Fig. 1d). After antibiotics were stopped, no recur-
rence was observed in 9 months of follow-up.
DISCUSSION
The standard treatment for non-tuberculous mycobac-
terial infections is a combination of antibiotics (9). 
The selection of antibiotics is usually based on drug 
susceptibility tests, yet the correlation between in vitro 
drug susceptibilities and in vivo treatment outcomes can 
be ambiguous for RGM infections (10). M. mageritense 
is known for its resistance to macrolides, which are often 
used for RGM infections; thus, an accurate identifica-
tion of the bacterial species is mandatory for effective 
treatment of infections (1). 
In general, the species within Mycobacteria are identi-
fied using PCR-based and/or DNA-DNA hybridization-
based methods in a clinical laboratory (11). However, 
M. mageritense is not identifiable using commercially 
available kits; and the more robust identification methods 
(PCR restriction enzyme analysis, 16S rRNA gene se-
quencing, and high-performance liquid chromatography) 
are complicated and time-consuming, delaying the 
selection and administration of appropriate antibiotics. 
Recently, MALDI-TOF MS has been widely used for 
species identification, in which a colony is picked from 
a culture plate and is directly submitted to the analysis 
chamber after drying (8). Since the analysis processes 
of MALDI-TOF MS itself takes only a few seconds, 
MALDI-TOF MS enabled us to identify M. mageritense 
in a day from the initiation of the examination, providing 
a theoretical basis for the selection and long-term admi-
nistration of antibiotics. This patient’s broadly distributed 
lesions were successfully treated using only antibiotics, 
although a surgical resection of remaining lesions is often 
required for the treatment of skin or subcutaneous tissue 
infections with M. mageritense (Table I). In addition, 
because of the paucity of evidence for the identification 
of the minor NTM, M. mageritense, by MALDI-TOF 
MS, we corroborated the result by the most robust met-
hod of full-length sequencing of the 16S rRNA. Further 
accumulation of data might certificate MALDI-TOF 
MS as a stand-alone method for the identification of M. 
mageritense. 
This report describes the clinical course of a case of 
subcutaneous infection with M. mageritense showing a 
broad distribution of abscesses. MALDI-TOF MS enab-
led the efficient identification of M. mageritense and thus 
its effective treatment with a combination of antibiotics.
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